Role of PE therapy in CIDP

What is the Role of PE therapy in CIDP? 

The efficacy of PE therapy in CIDP has been confirmed in two double-blind randomized controlled studies.

With careful monitoring, benefit usually can be demonstrated within 6 weeks though improvement can be transient. PE is most commonly used in

(1) the subgroup of patients with disability requiring treatment with immediate effectiveness while prednisone therapy is initiated;

(2) patients with intermittent acute exacerbations; and (

3) patients who are refractory or intolerant of other immunosuppressive therapies or in whom such therapies present substantial risks (e.g., diabetic or immunocompromised patients).

Approximately 20% to 30% of patients with CIDP become refractory to all other therapies and are dependent on long-term intermittent PE or intravenous immunoglobulin.

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top